In participants 18 years and older who have one F508del mutation and one minimal function mutation, some will receive VX-445, ivacaftor and tezacaftor, and others will receive placebo.
In participants who have two F508del mutations some will receive VX-445, ivacaftor and tezacaftor and others will receive placebo and ivacaftor and tezacaftor.
https://clinicaltrials.gov/ct2/show/NCT03227471?term=VX16-445-001&rank=1
In participants who have two F508del mutations some will receive VX-445, ivacaftor and tezacaftor and others will receive placebo and ivacaftor and tezacaftor.
https://clinicaltrials.gov/ct2/show/NCT03227471?term=VX16-445-001&rank=1